Hims & Hers Health, Inc. (NYSE:HIMS) Position Increased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd boosted its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 312.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 134,018 shares of the company's stock after purchasing an additional 101,536 shares during the quarter. Y Intercept Hong Kong Ltd owned about 0.06% of Hims & Hers Health worth $2,469,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of HIMS. Nisa Investment Advisors LLC raised its holdings in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock valued at $37,000 after buying an additional 1,603 shares during the period. Quest Partners LLC boosted its position in shares of Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company's stock worth $72,000 after buying an additional 3,507 shares during the period. CWM LLC boosted its position in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company's stock worth $110,000 after buying an additional 1,054 shares during the period. Van ECK Associates Corp purchased a new stake in shares of Hims & Hers Health during the 2nd quarter valued at about $111,000. Finally, Quarry LP raised its holdings in shares of Hims & Hers Health by 91.0% during the 3rd quarter. Quarry LP now owns 6,113 shares of the company's stock valued at $113,000 after buying an additional 2,913 shares during the period. Hedge funds and other institutional investors own 63.52% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on HIMS. TD Cowen reaffirmed a "buy" rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Piper Sandler reiterated a "neutral" rating and issued a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Bank of America downgraded Hims & Hers Health from a "buy" rating to an "underperform" rating and lowered their target price for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Needham & Company LLC assumed coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a "buy" rating and a $24.00 price target on the stock. Finally, Canaccord Genuity Group raised their price objective on Hims & Hers Health from $28.00 to $38.00 and gave the company a "buy" rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, Hims & Hers Health currently has an average rating of "Hold" and a consensus price target of $21.43.

Insider Transactions at Hims & Hers Health

In other news, CEO Andrew Dudum sold 45,767 shares of the company's stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $16.33, for a total value of $747,375.11. Following the completion of the sale, the chief executive officer now directly owns 67,015 shares of the company's stock, valued at approximately $1,094,354.95. This represents a 40.58 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Anja Manuel acquired 4,000 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were bought at an average price of $26.94 per share, for a total transaction of $107,760.00. Following the purchase, the director now directly owns 4,000 shares of the company's stock, valued at approximately $107,760. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders sold 974,495 shares of company stock worth $22,548,139. Company insiders own 17.71% of the company's stock.

Hims & Hers Health Trading Down 5.5 %

HIMS traded down $1.79 on Tuesday, hitting $30.85. 14,431,411 shares of the company's stock were exchanged, compared to its average volume of 9,929,937. The stock has a fifty day moving average of $23.82 and a two-hundred day moving average of $20.64. The firm has a market cap of $6.74 billion, a PE ratio of 69.32 and a beta of 1.25. Hims & Hers Health, Inc. has a twelve month low of $8.09 and a twelve month high of $35.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm's revenue for the quarter was up 77.1% on a year-over-year basis. During the same period last year, the company earned ($0.04) earnings per share. On average, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.